TipRanks
Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
:2595
Hong Kong Market
2595
Genfleet Therapeutics (Shanghai), Inc. Class H
RESEARCH TOOLSreports

Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

2595 Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Genfleet
Therapeutics (Shanghai), Inc. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2595 Stock 12 Month Forecast

Average Price Target

HK$52.24
▲(61.62% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Genfleet Therapeutics (Shanghai), Inc. Class H in the last 3 months. The average price target is HK$52.24 with a high forecast of HK$56.00 and a low forecast of HK$49.94. The average price target represents a 61.62% change from the last price of HK$32.32.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"HK$22","57":"HK$57","30.75":"HK$30.8","39.5":"HK$39.5","48.25":"HK$48.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.235,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$52.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$49.94</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,30.75,39.5,48.25,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,34.76923076923077,36.53846153846154,38.30769230769231,40.07692307692308,41.84615384615385,43.61538461538461,45.38461538461539,47.15384615384615,48.92307692307692,50.69230769230769,52.46153846153846,54.230769230769226,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,34.479615384615386,35.95923076923077,37.43884615384616,38.918461538461536,40.39807692307692,41.87769230769231,43.35730769230769,44.83692307692308,46.31653846153846,47.79615384615384,49.27576923076923,50.755384615384614,{"y":52.235,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,34.30307692307692,35.606153846153845,36.90923076923077,38.21230769230769,39.51538461538461,40.818461538461534,42.121538461538464,43.42461538461538,44.72769230769231,46.030769230769224,47.33384615384615,48.636923076923075,{"y":49.94,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.32,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.78,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.98,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.14,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.44,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.12,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$56.00Average Price TargetHK$52.24Lowest Price TargetHK$49.94
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BOCOM International Holdings Company Analyst forecast on HK:2595
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$51
Buy
57.80%
Upside
Reiterated
10/20/26
BOCOM International Holdings Company Remains a Buy on Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
Citic Securities Analyst forecast on HK:2595
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$56
Buy
73.27%
Upside
Reiterated
10/15/26
Citic Securities Sticks to Its Buy Rating for Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
Guotai Haitong Analyst forecast on HK:2595
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$49.37→HK$49.94
Buy
54.52%
Upside
Reiterated
09/06/26
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from Guotai Haitong
Goldman Sachs Analyst forecast on HK:2595
Linhai Percy Zhao, Ph.D.
Goldman Sachs
Not Ranked
Goldman Sachs
HK$52
Buy
60.89%
Upside
Initiated
08/30/26
Analyst Initiates Buy on GenFleet, Citing GFH276-Driven Valuation and Emerging Global RAS Franchise
Shenwan Hongyuan Analyst forecast on HK:2595
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$34.81
Buy
7.70%
Upside
Reiterated
06/30/26
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from Shenwan Hongyuan
SWS Res Analyst forecast on HK:2595
Unknown Analyst
SWS Res
Not Ranked
SWS Res
HK$34.81
Buy
7.70%
Upside
Reiterated
06/29/26
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from SWS Res
Sinolink Securities Analyst forecast on HK:2595
Unknown Analyst
Sinolink Securities
Not Ranked
Sinolink Securities
HK$55.63
Buy
72.12%
Upside
Reiterated
04/15/26
Sinolink Securities Sticks to Their Buy Rating for Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
CLSA Analyst forecast on HK:2595
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$61.9
Buy
91.52%
Upside
Reiterated
03/25/26
CLSA Reaffirms Their Buy Rating on Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BOCOM International Holdings Company Analyst forecast on HK:2595
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$51
Buy
57.80%
Upside
Reiterated
10/20/26
BOCOM International Holdings Company Remains a Buy on Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
Citic Securities Analyst forecast on HK:2595
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$56
Buy
73.27%
Upside
Reiterated
10/15/26
Citic Securities Sticks to Its Buy Rating for Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
Guotai Haitong Analyst forecast on HK:2595
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$49.37→HK$49.94
Buy
54.52%
Upside
Reiterated
09/06/26
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from Guotai Haitong
Goldman Sachs Analyst forecast on HK:2595
Linhai Percy Zhao, Ph.D.
Goldman Sachs
Not Ranked
Goldman Sachs
HK$52
Buy
60.89%
Upside
Initiated
08/30/26
Analyst Initiates Buy on GenFleet, Citing GFH276-Driven Valuation and Emerging Global RAS Franchise
Shenwan Hongyuan Analyst forecast on HK:2595
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$34.81
Buy
7.70%
Upside
Reiterated
06/30/26
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from Shenwan Hongyuan
SWS Res Analyst forecast on HK:2595
Unknown Analyst
SWS Res
Not Ranked
SWS Res
HK$34.81
Buy
7.70%
Upside
Reiterated
06/29/26
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from SWS Res
Sinolink Securities Analyst forecast on HK:2595
Unknown Analyst
Sinolink Securities
Not Ranked
Sinolink Securities
HK$55.63
Buy
72.12%
Upside
Reiterated
04/15/26
Sinolink Securities Sticks to Their Buy Rating for Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
CLSA Analyst forecast on HK:2595
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$61.9
Buy
91.52%
Upside
Reiterated
03/25/26
CLSA Reaffirms Their Buy Rating on Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

2595 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
2
3
4
4
5
Buy
3
2
2
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
6
4
5
In the current month, 2595 has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2595 average Analyst price target in the past 3 months is 52.24.
Each month's total comprises the sum of three months' worth of ratings.

2595 Financial Forecast

2595 Earnings Forecast

The previous quarter’s earnings for 2595 were -HK$3.24.
The previous quarter’s earnings for 2595 were -HK$3.24.

2595 Sales Forecast

The previous quarter’s earnings for 2595 were HK$45.46M.
The previous quarter’s earnings for 2595 were HK$45.46M.

2595 Stock Forecast FAQ

What is HK:2595’s average 12-month price target, according to analysts?
Based on analyst ratings, Genfleet Therapeutics (Shanghai), Inc. Class H’s 12-month average price target is 52.24.
    What is HK:2595’s upside potential, based on the analysts’ average price target?
    Genfleet Therapeutics (Shanghai), Inc. Class H has 61.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Genfleet Therapeutics (Shanghai), Inc. Class H a Buy, Sell or Hold?
          Genfleet Therapeutics (Shanghai), Inc. Class H has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Genfleet Therapeutics (Shanghai), Inc. Class H’s share price target?
            The average share price target for Genfleet Therapeutics (Shanghai), Inc. Class H is 52.24. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$56.00 ,and the lowest forecast is HK$49.94. The average share price target represents 61.62% Increase from the current price of HK$32.32.
              What do analysts say about Genfleet Therapeutics (Shanghai), Inc. Class H?
              Genfleet Therapeutics (Shanghai), Inc. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Genfleet Therapeutics (Shanghai), Inc. Class H?
                To buy shares of HK:2595, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.